Suppr超能文献

载脂蛋白结合腰围和体重指数预测代谢相关脂肪性肝病。

Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease.

机构信息

Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China.

Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.

出版信息

World J Gastroenterol. 2022 Sep 28;28(36):5364-5379. doi: 10.3748/wjg.v28.i36.5364.

Abstract

BACKGROUND

Early identification of metabolic-associated fatty liver disease (MAFLD) is urgent. Atherogenic index of plasma (AIP) is a reference predictor of obesity-related diseases, but its predictive value for MAFLD remains unclear. No studies have reported whether its combination with waist circumference (WC) and body mass index (BMI) can improve the predictive performance for MAFLD.

AIM

To systematically explore the relationship between AIP and MAFLD and evaluate its predictive value for MAFLD and to pioneer a novel noninvasive predictive model combining AIP, WC, and BMI while validating its predictive performance for MAFLD.

METHODS

This cross-sectional study consecutively enrolled 864 participants. Multivariate logistic regression analysis and receiver operating characteristic curve were used to evaluate the relationship between AIP and MAFLD and its predictive power for MAFLD. The novel prediction model A-W-B combining AIP, WC, and BMI to predict MAFLD was established, and internal verification was completed by magnetic resonance imaging diagnosis.

RESULTS

Subjects with higher AIP exhibited a significantly increased risk of MAFLD, with an odds ratio of 12.420 (6.008-25.675) for AIP after adjusting for various confounding factors. The area under receiver operating characteristic curve of the A-W-B model was 0.833 (0.807-0.858), which was significantly higher than that of AIP, WC, and BMI (all < 0.05). Subgroup analysis illustrated that the A-W-B model had significantly higher area under receiver operating characteristic curves in female, young and nonobese subgroups (all < 0.05). The best cutoff values for the A-W-B model to predict MAFLD in males and females were 0.5932 and 0.4105, respectively. Additionally, in the validation set, the area under receiver operating characteristic curve of the A-W-B model to predict MAFLD was 0.862 (0.791-0.916). The A-W-B level was strongly and positively associated with the liver proton density fat fraction ( = 0.630, < 0.001) and significantly increased with the severity of MAFLD ( < 0.05).

CONCLUSION

AIP was strongly and positively associated with the risk of MAFLD and can be a reference predictor for MAFLD. The novel prediction model A-W-B combining AIP, WC, and BMI can significantly improve the predictive ability of MAFLD and provide better services for clinical prediction and screening of MAFLD.

摘要

背景

早期识别代谢相关脂肪性肝病(MAFLD)迫在眉睫。血浆致动脉粥样硬化指数(AIP)是肥胖相关疾病的参考预测指标,但它对 MAFLD 的预测价值尚不清楚。尚无研究报道 AIP 与腰围(WC)和体重指数(BMI)联合是否可以提高对 MAFLD 的预测性能。

目的

系统探讨 AIP 与 MAFLD 的关系,评价其对 MAFLD 的预测价值,并开创一种新的无创预测模型,结合 AIP、WC 和 BMI,验证其对 MAFLD 的预测性能。

方法

本横断面研究连续纳入 864 名参与者。采用多变量 logistic 回归分析和受试者工作特征曲线评估 AIP 与 MAFLD 的关系及其对 MAFLD 的预测能力。建立了新型预测模型 A-W-B,联合 AIP、WC 和 BMI 预测 MAFLD,并通过磁共振成像诊断进行内部验证。

结果

AIP 较高的受试者 MAFLD 风险显著增加,在校正各种混杂因素后,AIP 的优势比为 12.420(6.008-25.675)。A-W-B 模型的受试者工作特征曲线下面积为 0.833(0.807-0.858),显著高于 AIP、WC 和 BMI(均 < 0.05)。亚组分析表明,在女性、年轻和非肥胖亚组中,A-W-B 模型的受试者工作特征曲线下面积显著更高(均 < 0.05)。A-W-B 模型预测男性和女性 MAFLD 的最佳截断值分别为 0.5932 和 0.4105。此外,在验证组中,A-W-B 模型预测 MAFLD 的受试者工作特征曲线下面积为 0.862(0.791-0.916)。A-W-B 水平与肝脏质子密度脂肪分数呈强正相关( = 0.630, < 0.001),并随 MAFLD 严重程度显著增加( < 0.05)。

结论

AIP 与 MAFLD 的风险呈强正相关,可作为 MAFLD 的参考预测指标。新型预测模型 A-W-B 联合 AIP、WC 和 BMI 可显著提高 MAFLD 的预测能力,为 MAFLD 的临床预测和筛查提供更好的服务。

相似文献

2
Cardiometabolic index: A new predictor for metabolic associated fatty liver disease in Chinese adults.
Front Endocrinol (Lausanne). 2022 Sep 16;13:1004855. doi: 10.3389/fendo.2022.1004855. eCollection 2022.
5
The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults.
Front Endocrinol (Lausanne). 2022 Nov 4;13:977625. doi: 10.3389/fendo.2022.977625. eCollection 2022.
6
Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in U.S. adults.
Front Endocrinol (Lausanne). 2023 Jan 19;14:1083032. doi: 10.3389/fendo.2023.1083032. eCollection 2023.
7
Elevated AIP is associated with the prevalence of MAFLD in the US adults: evidence from NHANES 2017-2018.
Front Endocrinol (Lausanne). 2024 May 14;15:1405828. doi: 10.3389/fendo.2024.1405828. eCollection 2024.
10
Comparison between traditional and new obesity measurement index for screening metabolic associated fatty liver disease.
Front Endocrinol (Lausanne). 2023 Apr 21;14:1163682. doi: 10.3389/fendo.2023.1163682. eCollection 2023.

引用本文的文献

1
Association between waist circumference and fatty liver disease in older adult population: a cross-sectional study in Urumqi.
Front Public Health. 2025 Jul 8;13:1620261. doi: 10.3389/fpubh.2025.1620261. eCollection 2025.
2
Association between the atherogenic index of plasma and testosterone deficiency in American adults: a cross-sectional study from NHANES 2011-2016.
Front Endocrinol (Lausanne). 2025 May 8;16:1531221. doi: 10.3389/fendo.2025.1531221. eCollection 2025.
6
Elevated AIP is associated with the prevalence of MAFLD in the US adults: evidence from NHANES 2017-2018.
Front Endocrinol (Lausanne). 2024 May 14;15:1405828. doi: 10.3389/fendo.2024.1405828. eCollection 2024.

本文引用的文献

2
Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2138-2147.e10. doi: 10.1016/j.cgh.2020.12.022. Epub 2020 Dec 22.
3
Redefining fatty liver disease: an international patient perspective.
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):73-79. doi: 10.1016/S2468-1253(20)30294-6. Epub 2020 Oct 5.
6
Metabolic liver disease in diabetes - From mechanisms to clinical trials.
Metabolism. 2020 Oct;111S:154299. doi: 10.1016/j.metabol.2020.154299. Epub 2020 Jun 20.
7
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.
8
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
Gastroenterology. 2020 May;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312. Epub 2020 Feb 8.
9
Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.
Lancet Gastroenterol Hepatol. 2020 Feb;5(2):167-228. doi: 10.1016/S2468-1253(19)30342-5. Epub 2019 Dec 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验